Opinion

Video

Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291

Erika P. Hamilton, MD, discusses the CAPItello-291 trial, which investigated the combination of capivasertib and fulvestrant in advanced HR+, HER2- locally advanced or metastatic breast cancer and led to its FDA approval, emphasizing the improved progression-free survival observed in patients with PIK3CA, AKT1, and PTEN alterations.

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Andrew Davis, MD
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Adrienne G. Waks, MD, Dana-Farber Cancer Institute
A panel of 3 experts on CLL
A panel of 3 experts on CLL
Video 8 - 2 KOLs are featured in, "Emerging Trials in the Management of HR+/HER2- mBC"